Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20)
Year: 2020
Type: conference-abstract
Source: Blood
Institutions: Genmab (United States), Genmab (Netherlands), Genmab (Denmark)
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3094948272
